All In Biotech

Drug Trial Radar · NCT02211729

A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children

Last checked: Nov 20, 2026Latest source record: Mar 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 22,090 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

22,090

Actual

Start

May 2014

Primary completion

Dec 31, 2017

Study completion Dec 31, 2017

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Malaria Research and Training Center, Bamako, Mali; Institut de Recherche en Sciences de la Sante, Burkina Faso
First posted
Aug 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 3 months, up to 59 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine whether addition of azithromycin (AZ) to Seasonal Malaria Chemoprevention (SMC) using sulphadoxine/pyrimethamine (SP) +amodiaquine (AQ) will provide an additional reduction in deaths and severe illness in young African children. The secondary objectives include an assessment of the safety and cost-effectiveness of the addition of AZ to SMC with SP+AQ. This a double blind, randomised, placebo controlled trial. The unit of randomisation will be the household. Children aged 3 - 59 months will be randomised to receive four cycles of either SP+AQ+AZ or SP+AQ+ placebo at monthly intervals during the peak malaria transmission season. Study Sites: Hounde district in Burkina Faso and in Bougouni district, Mali. Children of 3-59 months of age at the start of each period of drug administration will be eligible for inclusion in the trial provided that parental consent is obtained. Children with a severe, chronic illness or known allergy to one of the study drugs will be excluded. Primary endpoint: Incidence of the combination of death or hospital admission for at least 24 hours, not due to trauma or elective surgery during the intervention period Secondary endpoints: 1. incidence of the primary endpoint during the whole study period 2. attendance at a study health centre with a nonmalaria febrile illness 3. attendance at a study health centre with malaria, 4. the prevalence of moderate anaemia at the end of each malaria transmission season, 5. nutritional status at the end of each malaria transmission season, 6. prevalence of nasopharyngeal carriage with pneumococci and macrolide resistant pneumococci before and at the end of each malaria transmissions season, 7. prevalence of resistance markers to SP at the end of the study, Sample size: 19,200 children (9600 in each country) will be enrolled.

Conditions

  • Malaria
  • Respiratory Infections

Interventions

  • Sulphadoxine-Pyrimethamine+ Amodiaquine+ AzithromycinDrug

    Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season

  • Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycinDrug

    Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. severe morbidity and mortalityTime frame: from the time of enrolment upto the end of malaria transmission in year 3 ( the person time at risk will be restricted to three malaria transmission seasons)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Hounde district Hospital

    Houndé, Burkina Faso

  • Bougouni Koulikoro District hospital

    Bougouni, Mali

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.